Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

Serum neurofilament is associated with progression of brain atrophy and disability in early MS

(2017) Jens Kuhle et al.   NEUROLOGY

Blood-based NfL

(2017) Oskar Hansson et al.   NEUROLOGY

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis

(2016) Lenka Novakova et al.   JOURNAL OF NEUROCHEMISTRY

TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE

(2016) C Alvarez-Gonzalez et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

(2016) Jonathan D. Rohrer et al.   NEUROLOGY

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

(2016) Mehtap Bacioglu et al.   NEURON

Imaging as an Outcome Measure in Multiple Sclerosis

(2016) Daniel Ontaneda et al.   Neurotherapeutics

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

(2016) Henrik Zetterberg et al.   JAMA Neurology

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

(2016) Julio C. Rojas et al.   Annals of Clinical and Translational Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury

(2016) Pashtun Shahim et al.   Scientific Reports

Exploring the origins of grey matter damage in multiple sclerosis

(2015) Massimiliano Calabrese et al.   NATURE REVIEWS NEUROSCIENCE

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction

(2015) Mattias Vågberg et al.   PLoS One

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

Body fluid biomarkers in multiple sclerosis

(2013) Manuel Comabella et al.   LANCET NEUROLOGY

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

A comparative study of CSF neurofilament light and heavy chain protein in MS

(2013) Jens Kuhle et al.   Multiple Sclerosis Journal

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers

(2013) Mohsen Khademi et al.   PLoS One

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

(2013) Sharmilee Gnanapavan et al.   PLoS One

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis

(2010) Emma C Tallantyre et al.   Multiple Sclerosis Journal